Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 9, 2021 7:30 AM EDTCAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.
Second quarter CAPLYTA total prescriptions (TRx) increased 22% versus the previous quarter.
Total revenues for the second quarter were $20.0 million. CAPLYTA achieved net product revenues of $19.0 million for the second quarter.
Patient enrollment in Study 501, a Phase 3 clinical trial evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD), has commenced.
NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.... More
